Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | MCL1 | Q07820 | 14/20 | 0.63 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | BCL2 | P10415 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514964 | 1.00 | FOLH1 (1.00) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL5955774 | 0.85 | ALDH1A1 (0.74) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL29432490 | 0.84 | KDM4E (1.00) | FOLH1KDM4EALDH1A1MCL1 | |
| SCHEMBL2003146 | 0.84 | KDM4E (0.72) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL9188195 | 0.84 | KDM4E (1.00) | FOLH1KDM4EALDH1A1MCL1 | |
| SCHEMBL2002751 | 0.83 | FOLH1 (0.71) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL13701155 | 0.83 | KDM4E (0.71) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL3205801 | 0.81 | KDM4E (0.69) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL29621784 | 0.81 | KDM4E (0.69) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL5971268 | 0.81 | KDM4E (0.68) | FOLH1KDM4EALDH1A1MCL1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802153-B2 | System for targeted delivery of therapeutic agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-08-12 | — | — | US | claimed |
| US-8709483-B2 | System for targeted delivery of therapeutic agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-04-29 | — | — | US | claimed |
| US-7148250-B2 | Indoles as NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 2006-12-12 | — | — | US | claimed |
| US-20050080128-A1 | Indoles as naaladase inhibitors | EISAI INC. | 2005-04-14 | — | — | US | claimed |
| WO-2003057670-A2 | INDOLES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-07-17 | — | — | WO | claimed |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | CYTODIGM, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260000771-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2026-01-01 | — | — | US | disclosed |
| US-20260000700-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2026-01-01 | — | — | US | disclosed |
| US-20250135014-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2025-05-01 | — | — | US | disclosed |
| US-20240358653-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | CYTODIGM, INC. | 2024-10-31 | — | — | US | disclosed |
| US-12070508-B2 | Microparticles and nanoparticles having sulfate groups on the surface | CYTODIGM, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| WO-2024100040-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2009110939-A2 | DRUG DELIVERY SYSTEM FOR PHARMACEUTICALS AND RADIATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090061010-A1 | CANCER CELL TARGETING USING NANOPARTICLES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-03-05 | — | — | US | disclosed |
| EP-2007435-A2 | SYSTEM FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | The Brigham and Women's Hospital, Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008105773-A2 | SYSTEM FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2007150030-A2 | MICROFLUIDIC SYNTHESIS OF ORGANIC NANOPARTICLES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-12-27 | — | — | WO | disclosed |
| US-7148250-B2 | Indoles as NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050080128-A1 | Indoles as naaladase inhibitors | EISAI INC. | 2005-04-14 | — | — | US | disclosed |
| WO-2003057670-A2 | INDOLES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250135014-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | DCLRE1A, LIG3, LARS1 | FOLH1 1505/4885KDM4E 4155/4885ALDH1A1 1583/4885 |
| US-20050080128-A1 | Indoles as naaladase inhibitors | NAALAD2, RIMKLA, NGF | FOLH1 8/4885KDM4E 3250/4885ALDH1A1 158/4885 |
| US-20260000771-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | PSMA1, PSMA3, PSMA2 | FOLH1 9/4885KDM4E 3243/4885ALDH1A1 2457/4885 |
| US-20260000700-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | CTDSP1, POLM, MCTS1 | FOLH1 1294/4885KDM4E 4503/4885ALDH1A1 2992/4885 |
| US-20090061010-A1 | CANCER CELL TARGETING USING NANOPARTICLES | CD47, EPCAM, CD44 | FOLH1 279/4885KDM4E 3494/4885ALDH1A1 1446/4885 |
| US-20240358653-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | SIGLEC9, SIGLEC7, SELPLG | FOLH1 1197/4885KDM4E 4807/4885ALDH1A1 1402/4885 |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | SIGLEC7, SIGLEC9, CD2 | FOLH1 1488/4885KDM4E 1349/4885ALDH1A1 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.